Sigma-Aldrich Expands Position in Whole Genome Amplification
News Feb 20, 2006
Sigma-Aldrich has announced a licensing agreement with Rubicon Genomics that allows Sigma to offer GenomePlex® Whole Genome Amplification (WGA) kits to service providers.
Under this agreement, Sigma-Aldrich may sell GenomePlex kits to companies offering Whole Genome Amplification Services, thus expanding the service market to archived samples, FFPE and single cells.
Rubicon Genomics will retain all rights to WGA for molecular diagnostics, and will continue its existing service business.
"This licensing agreement enables Sigma-Aldrich to partner with service providers that offer genetic processing capabilities and expertise," said Keith Jolliff, Director of Strategic Marketing at Sigma-Aldrich.
"Market Research shows that thirty percent of customers are currently using service companies for WGA. However, service providers have been limited in their ability to amplify DNA from damaged or degraded sources, such as FFPE or archived samples, and from single cells."
"This agreement allows Sigma-Aldrich to more broadly share our enhancements of the GenomePlex technology to enable service providers to more effectively meet the needs of researchers."
In 2004 Sigma-Aldrich announced an exclusive licensing agreement with Rubicon Genomics to further develop and commercialize the GenomePlex WGA technology.
At that time, Rubicon Genomics retained all rights to WGA for molecular diagnostics and services. Sigma-Aldrich's success with the GenomePlex technology has led to the development of several kits that offer accurate amplification.
The latest addition to the product family is the GenomePlex Single Cell WGA Kit, which is designed to support whole genome amplification from a single cell and results in a million-fold amplification of genomic DNA.
GenomePlex is a proprietary amplification method based on random fragmentation of the genome into a series of overlapping, short templates.
The resulting shorter DNA strands are efficiently primed and amplified to generate a library of DNA fragments with defined 3' and 5' termini, or the OmniPlex® library.
This library is replicated using a linear, isothermal amplification in the initial stages, followed by a limited round of geometric (PCR) amplifications.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.